The Impact of Itraconazole, a Strong CYP3A4 Inhibitor, on the Pharmacokinetics and Safety of Camlipixant in Healthy Participants 🔗 Access full article via Journal of Allergy and Clinical ImmunologyShare:TwitterFacebookEmailRedditMoreLinkedInWhatsAppTelegramMastodon
